Enzyme-inducing antiseizure medications (EIASMs) increase the risk for new-onset cardiovascular events among older adults with epilepsy, a new study suggests. In a prospective cohort study of […]

PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s disease (PD), was shown to significantly reduce disease burden in two […]

Getting drugs to the brain is difficult. The very thing designed to protect the brain’s environment — the blood-brain barrier (BBB), tightly packed cells that prevent […]

PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s disease (PD), was shown to significantly reduce disease burden in two […]

A strategy developed by Canadian researchers for encouraging older patients with insomnia to wean themselves from sleeping pills and improve their sleep through behavioral techniques is […]

(Reuters) -Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer’s disease after it failed to meet the main goal of […]

COPENHAGEN — Serum glial fibrillary acidic protein (sGFAP) is quickly maturing as a biomarker to predict disability in patients with multiple sclerosis (MS), but it will […]